Two years ago, Coherus BioSciences shelved development of its wholly-owned CHS-2020 biosimilar Eylea (aflibercept) candidate, several times expressing confidence that with its Cimerli (ranibizumab-eqrn) biosimilar, the company had the “ability to not only penetrate a high degree of Lucentis (ranibizumab) [patients], but also those edges of [off-label] Avastin (bevacizumab) and Eylea (aflibercept).”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?